| Stock | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| Gritstone bio, Inc. | EVP, Head of Research and Development | Common Stock | 684K | $511K | $0.75 | May 16, 2024 | Direct |
| FATE THERAPEUTICS INC | Director | Stock Option (Right to Buy) | 40K | $109K | $2.73 | Jun 7, 2024 | Direct |
| Gritstone bio, Inc. | EVP, Head of Research and Development | Stock Option (Right to Buy) | 235K | May 15, 2024 | Direct |
| Symbol | Company | Period | Transactions | Value $ | Form Type | Date Filed | Role |
|---|---|---|---|---|---|---|---|
| FATE | FATE THERAPEUTICS INC | Jun 7, 2024 | 1 | $0 | 4 | Jun 11, 2024 | Director |
| GRTS | Gritstone bio, Inc. | May 15, 2024 | 3 | -$10.3K | 4 | May 17, 2024 | EVP, Head of Research and Development |
| GRTS | Gritstone bio, Inc. | Feb 1, 2024 | 2 | $0 | 4 | Feb 5, 2024 | EVP, Head of Research and Development |
| FATE | FATE THERAPEUTICS INC | Jun 6, 2023 | 1 | $0 | 4 | Jun 7, 2023 | Director |
| GRTS | Gritstone bio, Inc. | Feb 2, 2023 | 1 | $0 | 4 | Feb 6, 2023 | Executive Vice President and Head of Research and Development |
| FATE | FATE THERAPEUTICS INC | Jun 9, 2022 | 2 | $0 | 4 | Jun 13, 2022 | Director |
| FATE | FATE THERAPEUTICS INC | Jun 3, 2022 | 1 | -$33.8K | 4 | Jun 6, 2022 | Director |
| GRTS | Gritstone bio, Inc. | Jan 31, 2022 | 2 | $0 | 4 | Apr 20, 2022 | Executive Vice President and Head of Research and Development |
| FATE | FATE THERAPEUTICS INC | Jun 2, 2021 | 2 | $0 | 4 | Jun 4, 2021 | Director |
| GRTS | Gritstone bio, Inc. | Jan 7, 2021 | 1 | $0 | 4 | Nov 19, 2021 | Executive Vice President and Chief Scientific Officer |